C4 Therapeutics (CCCC) Insider Roy Buys 62,000 Shares

Grogan Donna Roy recently bought 62,000 shares of CCCC. This insider transaction took place on June 24, 2026, indicating a level of confidence in the company. The stock traded near $4.40 on Saturday, reflecting the market's current valuation.

Other Institutional Activity in CCCC

Morgan Stanley grew its holdings in CCCC by 90,738 shares, bringing its total to 9,072,400 shares valued at approximately $23.86 million. RA Capital Management, L.P. maintained its position at 8,000,000 shares worth $21.04 million. Bain Capital Life Sciences Investors, LLC also held steady at 7,171,910 shares, valued at $18.86 million. Lynx1 Capital Management LP reduced its stake by 99,231 shares, now holding 6,998,902 shares valued at $18.41 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,861,852 shares, valued at about $10.16 million.

C4 Therapeutics, Inc. Stock Up 29.8%

Shares of CCCC traded near $4.40 on Saturday. Although specific data on market cap, P/E ratio, and beta were not provided, the stock's recent activity and insider purchases suggest ongoing interest and potential volatility.

Insider Buying and Selling at C4 Therapeutics, Inc.

Several insiders, including Donna Roy Grogan, Laura Bessen, and Stephen Fawell, each purchased 62,000 shares of CCCC on June 24, 2026. These transactions were not made under a Rule 10b5-1 trading plan, indicating discretionary buying. Kenneth Carl Anderson also made several transactions, including buying 1,070 shares on June 1, 2026, at $2.11 per share, and 4,259 shares on April 1, 2026, at $2.70 per share.

Analysts Set New Price Targets

On June 1, 2026, Evercore ISI Group maintained its 'buy' rating for CCCC, setting a price target of $12.0. Barclays has consistently maintained a 'buy' rating as well, with varying targets, the most recent being $7.0 on February 27, 2026. The general consensus among analysts remains positive, with a 'buy' recommendation and an average price target reflecting optimism.

Bottom Line

Grogan Donna Roy's purchase of 62,000 shares of CCCC highlights ongoing insider confidence in the company. This activity is important for investors tracking insider moves, as it can indicate potential future performance. Remember, these insider transactions are disclosed after they occur, providing a historical snapshot rather than a current recommendation.